Can the Leibovich score for clear cell renal cell carcinoma (ccRCC) be accurately reported by a general pathologist?

被引:3
|
作者
Vasdev, Nikhil [1 ]
Altal, Yaman [1 ]
Mafeld, Sebastian [1 ]
Wong, Kevin [1 ]
Chadwick, David [1 ]
Gowda, Basavaraj D. R. [1 ]
Mutton, Adrienne [2 ]
Nagarajan, Srikantiah [2 ]
Bhatti, Aftab [1 ]
机构
[1] James Cook Univ Hosp, Dept Urol, Middlesbrough TS4 3BW, Cleveland, England
[2] James Cook Univ Hosp, Dept Histopathol, Middlesbrough TS4 3BW, Cleveland, England
关键词
Leibovich score; renal cell carcinoma (RCC); pathology; RADICAL NEPHRECTOMY; PREDICTION;
D O I
10.1111/bju.12337
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate the accuracy of reporting of the Leibovich score (LS) by general pathologists at our centre by comparing the LS in their initial reports with the LS in subsequent review reports by our specialist urological pathologists. We also assessed whether a revision in the LS subsequently altered the risk group. Patients and MethodsIn all, 54 consecutive patients had had their initial histology after nephrectomy reported by a general pathologist between August 2008 and March 2012. The histological slides were subsequently re-reviewed by the two specialist urological pathologists and revised LS were given if appropriate. The cases were then discussed at the Uro-oncology Multi disciplinary meeting (MDT) and the reason for the revised LS was discussed with the participating panel and reviewed by the uropathologist. Results The general pathologists allocated the 54 patients into low- (13 patients), intermediate- (25) and high-risk (16) categories. After a review of the slides by the specialist urological pathologists and discussion at the MDT meeting the LS was revised in 23 patients (42.6%). The 23 patients who had their LS revised were divided into two groups for the purpose of the present study. On revision of the LS a total of eight patients (14.8%) changed their prognostic group. The change in the prognostic group in the eight patients was increased from intermediate- to high-risk in four patients. There was a reduction in the LS in four patients, which was from high- to intermediate-risk category in one patient and intermediate- to low-risk in three patients. Conclusion In the present study, histopathology review by a specialist urological pathologist led to a change in LS in 42.6% of cases leading a change in risk grouping in 14.8% of cases. This level of discrepancy is not insignificant. However, the few cases evaluated in the present study does limit robust conclusions and further studies are needed to investigate this issue, so that recommendations can be made to enhance diagnostic accuracy and reproducibility.
引用
收藏
页码:581 / 585
页数:5
相关论文
共 50 条
  • [1] Prognostic Value of the Leibovich Prognosis Score Supplemented by Vascular Invasion for Clear Cell Renal Cell Carcinoma
    Pichler, Martin
    Hutterer, Georg C.
    Chromecki, Thomas F.
    Jesche, Johanna
    Groselj-Strele, Andrea
    Kampel-Kettner, Karin
    Pummer, Karl
    Zigeuner, Richard
    [J]. JOURNAL OF UROLOGY, 2012, 187 (03): : 834 - 839
  • [2] The lipid metabolome of clear cell renal cell carcinoma (CCRCC).
    George, Saby
    Choi, Kyoung-Soo
    Pili, Roberto
    Kazim, Abdul Latif
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] The lipid metabolomic profile of clear cell renal cell carcinoma (CCRCC)
    George, S.
    Choi, K-S
    Miecznikowski, J.
    Pili, R.
    Kazim, A. L.
    [J]. BJU INTERNATIONAL, 2012, 110 : 15 - 16
  • [4] Prognostic biomarkers in patients with clear cell renal cell carcinoma (ccRCC)
    Gandur Quiroga, Maria N.
    Knott, Maria E.
    Pulero, Carla
    Pasik, Leonardo
    Alvarez, Ana M.
    Brzezinski, Mariano
    Malagrino, Hector
    Bal de Kier Joffe, Elisa D.
    Puricelli, Lydia I.
    [J]. CANCER RESEARCH, 2012, 72
  • [5] Expression of erythropoietin and neuroendocrine markers in clear cell renal cell carcinoma (CCRCC)
    Mjones, P.
    Nordrum, I.
    Qvigstad, G.
    Sordal, O.
    Rian, L. L. Martensson
    Waldum, H. L.
    [J]. VIRCHOWS ARCHIV, 2017, 471 : S283 - S283
  • [6] Immunobiochemical profile of clear cell renal cell carcinoma (ccRCC): A preliminary study
    Vargova, Daniela
    Dargaj, Jan
    Franova, Sona
    Dohal, Matus
    Luptak, Jan
    Svihra, Jan
    Bris, Lukas
    Grendar, Marian
    Sutovska, Martina
    [J]. GENERAL PHYSIOLOGY AND BIOPHYSICS, 2023, 42 (05) : 387 - +
  • [7] Identification of Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma (ccRCC) by Transcriptomics
    Zhang, Sihong
    Xu, Xianglai
    Wang, Yelin
    Zhu, Yanjun
    Wang, Jiajun
    Wang, Hang
    Guo, Jianming
    [J]. ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2021, 51 (05): : 597 - 608
  • [8] Differencial proteome of clear-cell renal cell carcinoma (ccRCC) tissues
    Vieira de Ribeiro, Ana Julia
    Sandim, Vanessa
    Ornellas, Antonio Augusto
    Reis, Rodrigo Siqueira
    Domont, Gilberto
    Alves, Gilda
    [J]. INTERNATIONAL BRAZ J UROL, 2013, 39 (01): : 83 - 94
  • [9] Novel biomarkers and therapeutic targets in clear cell renal cell carcinoma (ccRCC)
    Meseguer Navarro, Anna
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 125 : 17 - 18
  • [10] Transcriptional (mRNA) Profiling in Clear Cell Renal Cell Carcinoma (CCRCC): Comparison of CCRCC to Non-Neoplastic Renal Tissue
    Bastacky, S. I.
    Bastacky, M. L.
    Roy, S.
    Parwani, A. V.
    Dhir, R.
    Lyons-Weiler, M. A.
    Sciulli, C. M.
    Krill-Burger, M.
    Amin, M.
    LaFramboise, W. A.
    [J]. LABORATORY INVESTIGATION, 2013, 93 : 196A - 196A